Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 37

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 37
---
 salary of $350,000 pro-rated for Mr. Ballantyne’s time as Chief Financial Officer from April 10, 2023 through December 31, 2023. |

NARRATIVE TO SUMMARY COMPENSATION TABLE Elements of Compensation Our Board reviews compensation annually for all employees, including our named executive officers. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to our company. Generally, our Board has historically determined the compensation of our executives, upon recommendation of the Compensation Committee. The Compensation Committee has reviewed and recommended to the Board for approval the compensation and other terms of employment of our Chief Executive Officer and evaluates the Chief Executive Officer’s performance in light of relevant corporate goals and objectives. Our Chief Executive Officer has typically discussed his recommendations for all other executives (other than himself) with the compensation committee and the Board. Based on those discussions and its discretion, the Compensation Committee has recommended the cash compensation of each executive officer to the Board, and the Board has then approved. The Compensation Committee administers our equity compensation plans and approves or recommends to the Board for approval awards made to our executives thereunder. Annual Base Salary The annual base salaries of our named executive officers are generally reviewed, determined and approved by the Board periodically upon the recommendation of the Compensation Committee in order to compensate our named executive officers for the satisfactory performance of duties to our company. Annual base salaries are intended to provide a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent. The following table sets forth the annual base salaries for each of our named executive officers for the years indicated:

| ​                     | ​ |         ​ | ​ |         ​ | ​ |
| ​                     |   | 2024 Base |   | 2025 Base |   |
| ​                     | ​ |    Salary | ​ |    Salary | ​ |
| Name                  | ​ |        -$ | ​ |        -$ | ​ |
| Gene Mack(1)          |   |   370,000 | ​ |   500,000 | ​ |
| Gianluca Fuggetta(2)  |